Otsuka's NDA for Tolvaptan for Autosomal Dominant Polycystic Kidney Disease , Accepted for Review by FDA

Otsuka Pharmaceutical Co OTSKY announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review the company's new drug application (NDA) for the potential use of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD). Phase III clinical trial results that form the basis of the regulatory filing were published online in the New England Journal of Medicine.1 ADPKD is a hereditary genetic illness characterized by the development of multiple cysts in the kidneys. ADPKD is the most common inherited kidney disease and the fourth most common overall cause of kidney failure worldwide, with the diagnosed prevalence estimated to be between 1:1,000 and 1:4,000 globally. See full press release
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceGlobal
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!